All In Biotech

Drug Trial Radar · NCT06724614

Efficacy and Safety of VDPHL01 in Males With AGA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Nov 6, 2024

Primary completion

Feb 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Veradermics, Inc.Industry
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.

Conditions

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Interventions

  • VDPHL01Drug

    VDPHL01 Extended Release (ER) Tablet

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
  2. Subjects Evaluation of Treatment BenefitTime frame: Month 6

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Site 36

    Birmingham, Alabama

  • Site 28

    Phoenix, Arizona

  • Site 30

    Fort Smith, Arkansas

  • Site 35

    Rogers, Arkansas

  • Site 07

    Fountain Valley, California

  • Site 02

    Fremont, California

  • Site 34

    Sherman Oaks, California

  • Site 21

    Vista, California

  • Site 05

    Castle Rock, Colorado

  • Site 24

    Englewood, Colorado

  • Site 17

    Aventura, Florida

  • Site 25

    Brandon, Florida

  • Site 42

    Hollywood, Florida

  • Site 03

    Tampa, Florida

  • Site 43

    Atlanta, Georgia

  • Site 31

    Boise, Idaho

  • Site 23

    Rolling Meadows, Illinois

  • Site 15

    Indianapolis, Indiana

  • Site 32

    New Albany, Indiana

  • Site 27

    West Lafayette, Indiana

  • Site 41

    Baton Rouge, Louisiana

  • Site 13

    Covington, Louisiana

  • Site 12

    Metairie, Louisiana

  • Site 22

    Brighton, Massachusetts

  • Site 26

    Clarkston, Michigan

  • Site 06

    New Brighton, Minnesota

  • Site 18

    Hackensack, New Jersey

  • Site 37

    Kew Gardens, New York

  • Site 38

    New York, New York

  • Site 39

    Boardman, Ohio

  • Site 11

    Columbus, Ohio

  • Site 08

    Broomall, Pennsylvania

  • Site 10

    Plymouth Meeting, Pennsylvania

  • Site 20

    Greensville, South Carolina

  • Site 09

    Knoxville, Tennessee

  • Site 16

    Murfreesboro, Tennessee

  • Site 04

    Nashville, Tennessee

  • Site 40

    Bellaire, Texas

  • Site 44

    Dallas, Texas

  • Site 14

    Houston, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.